Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 12:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,208 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Completed Phase 4 Interventional

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

NCT05657860
View directory record Official record
Conditions
Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
Interventions
Guanfacine Extended Release, Placebo
Drug · Other
Lead sponsor
Maimonides Medical Center
Other
Eligibility
6 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Indomethacin Versus Nifedipine for Preterm Labor Tocolysis

NCT00486824
View directory record Official record
Conditions
Obstetric Labor, Premature
Interventions
Indomethacin, Nifedipine
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals

NCT01433289
View directory record Official record
Conditions
HIV Infection
Interventions
Polyphenon E, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 14, 2026, 12:03 PM EDT
Recruiting Not applicable Interventional

Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)

NCT04557891
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Active LIFUP Treatment, Sham LIFUP Treatment
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 1 Interventional

Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin

NCT00269061
View directory record Official record
Conditions
Non-Insulin-Dependent Diabetes Mellitus
Interventions
pioglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2008 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 3 Interventional Results available

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis

NCT00783718
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
vedolizumab, Placebo
Drug · Other
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
102
States / cities
Birmingham, Alabama • Los Angeles, California • Montebello, California + 82 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

NCT00413660
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
33
States / cities
Gilbert, Arizona • Hot Springs, Arkansas • Upland, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

NCT02659020
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Olaratumab, Gemcitabine, Docetaxel, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
16 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
21
States / cities
Santa Monica, California • Aurora, Colorado • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Magnesium vs Placebo for Tonsillectomy

NCT02218424
View directory record Official record
Conditions
Pain
Interventions
Magnesium, Normal saline
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
4 Years to 10 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

Stress Response and Neurodevelopmental Outcome After Cardiac Surgery Utilizing CPB in Children: A Prospective, Double Blinded and Randomized Study

NCT02492269
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Aymen N Naguib
Other
Eligibility
1 Month to 12 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 4 Interventional Results available

Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM

NCT03608774
View directory record Official record
Conditions
Anal Chlamydia Infection
Interventions
Azithromycin, Doxycycline, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 14, 2026, 12:03 PM EDT
Terminated Phase 2 Interventional Results available

A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA

NCT05462990
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
QUC398, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Tampa, Florida • Boston, Massachusetts • Morehead City, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars

NCT00892723
View directory record Official record
Conditions
Scar Prevention, Scar Reduction
Interventions
AZX100 Drug Product, Placebo
Drug
Lead sponsor
Capstone Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Pasadena, California • Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Research Study Investigating Mim8 in People With Haemophilia A

NCT04204408
View directory record Official record
Conditions
Healthy Volunteers, Haemophilia A With or Without Inhibitors
Interventions
NNC0365-3769 (Mim8), Placebo (Mim8)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug

NCT04299490
View directory record Official record
Conditions
Sleep Disorder, Healthy
Interventions
Sleep Fragmentation, Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo), Sleep Continuity Disruption, Undisturbed Sleep
Behavioral · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 48 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 3 Interventional Results available

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02107196
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
65
States / cities
Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 1 Interventional

Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis

NCT02049203
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Ataciguat, Placebo
Drug
Lead sponsor
Jordan D. Miller, Ph.D.
Other
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

NCT04972227
View directory record Official record
Conditions
Schizophrenia
Interventions
CY6463, Placebo
Drug
Lead sponsor
Tisento Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Long Beach, California • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

NCT02059291
View directory record Official record
Conditions
Hereditary Periodic Fevers
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 14, 2026, 12:03 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Chronic Consumption of Vinegar on Visceral Adiposity in Overweight Adults (VAnish)

NCT04706520
View directory record Official record
Conditions
Body Composition
Interventions
Study Beverage Consumption
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 14, 2026, 12:03 PM EDT
Recruiting Phase 3 Interventional

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

NCT07623161
View directory record Official record
Conditions
Myelofibrosis, Anemia
Interventions
Placebo, Elritercept
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
30
States / cities
Gilbert, Arizona • Glendale, California • Whittier, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

NCT03097861
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
67
States / cities
Birmingham, Alabama • Foley, Alabama • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

NCT02725515
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
XmAb5871, Placebo to match XmAb5871
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
La Jolla, California • Loma Linda, California • San Leandro, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 14, 2026, 12:03 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

NCT03347708
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
IDCT, Saline Solution, Sodium Hyaluronate
Biological · Drug
Lead sponsor
DiscGenics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 14, 2026, 12:03 PM EDT